https://www.youtube.com/watch?v=stLIHSo6-50
Is Mesoblast Going To Fly After FDA Approval?!| (ASX: MSB) | ASX Growth Stocks

Today we analyse our stock of the day - Mesoblast (ASX: MSB).
Mesoblast is an ASX Healthcare stock that utilises cell-based technology to develop innovative treatments to treat serious and life-threatening diseases.
Mesoblast has a significant product pipeline with numerous candidates in the process of Phase-3 trials on the path to FDA approval - today we discuss if their lead candidate Ryoncil (Remestecel-L) is approved by the FDA what will happen to Mesoblast and the MSB share-price.
Mesoblast is one of the most exciting healthcare and bio-tech companies on the ASX 200 and is one of the great ASX healthcare stocks to watch!